Kymera Therapeutics, Inc. (KYMR) Ownership
KYMR ownership summary
as of October 18, 2026- Institutions
- 119.4% of shares outstanding
- Insiders
- 2.12% of shares outstanding
- Shares outstanding
- 82.3M
- Float
- 66.0M shares available to trade
- Short interest
- 15.33% 9.9M shares short
- Days to cover
- 13.18 short interest down 5.9% vs prior month
- Institutions 119.38%
- Insiders 2.12%
KYMR top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.85% | 12.3M | $1.29B | +649,306 (+5.5%) | June 30, 2026 |
| 2 | Baker Bros Advisors LP | 10.41% | 8.7M | $907.1M | — | June 30, 2026 |
| 3 | venBio Select Advisor LLC | 8.99% | 7.5M | $783.2M | — | June 30, 2026 |
| 4 | T. Rowe Price Associates, Inc. | 8.55% | 7.1M | $745.3M | +1.1M (+17.4%) | June 30, 2026 |
| 5 | T. Rowe Price Investment Management,Inc. | 7.53% | 6.3M | $655.6M | +792,264 (+14.5%) | June 30, 2026 |
| 6 | BlackRock Inc | 6.66% | 5.5M | $580.3M | +477,334 (+9.4%) | June 30, 2026 |
| 7 | Bvf Inc | 4.66% | 3.9M | $405.7M | −1.6M (−29.6%) | June 30, 2026 |
| 8 | Wellington Management Company LLP | 4.42% | 3.7M | $385.1M | −214,659 (−5.5%) | June 30, 2026 |
| 9 | Vanguard Portfolio Management, LLC | 3.60% | 3.0M | $313.5M | +118,137 (+4.1%) | June 30, 2026 |
| 10 | Siren, L.L.C. | 3.53% | 2.9M | $307.6M | −251,000 (−7.9%) | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 3.53% | 2.9M | $307.3M | +52,054 (+1.8%) | June 30, 2026 |
| 12 | Atlas Venture Life Science Advisors, LLC | 3.42% | 2.8M | $298.4M | −1.7M (−37.8%) | June 30, 2026 |
| 13 | State Street Corp | 3.29% | 2.7M | $286.8M | +347,459 (+14.5%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.18% | 1.8M | $190.3M | +170,981 (+10.4%) | June 30, 2026 |
| 15 | Capital Research Global Investors | 1.67% | 1.4M | $145.5M | −284,394 (−17.0%) | June 30, 2026 |
| 16 | The Goldman Sachs Group Inc | 1.43% | 1.2M | $124.4M | +298,924 (+33.6%) | June 30, 2026 |
| 17 | UBS Group AG | 1.21% | 1.0M | $105.6M | −16,075 (−1.6%) | June 30, 2026 |
| 18 | AllianceBernstein L.P. | 1.18% | 982K | $102.8M | +93,486 (+10.5%) | June 30, 2026 |
| 19 | Driehaus Capital Management LLC | 1.11% | 919K | $96.3M | −124,350 (−11.9%) | June 30, 2026 |
| 20 | Merck & Co Inc | 0.93% | 772K | $80.9M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 4.1M shares and 7 cut 4.3M.
KYMR top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 2.70% | 2.2M | $234.9M | +8,800 (+0.4%) | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.52% | 2.1M | $219.4M | −2,836 (−0.1%) | August 31, 2026 |
| 3 | T. Rowe Price New Horizons | 2.43% | 2.0M | $211.7M | −59,063 (−2.8%) | August 31, 2026 |
| 4 | Vanguard Health Care Inv | 2.16% | 1.8M | $188.2M | — | June 30, 2026 |
| 5 | iShares Russell 2000 ETF | 1.95% | 1.6M | $169.9M | −14,491 (−0.9%) | September 30, 2026 |
| 6 | Vanguard Small Cap Index | 1.82% | 1.5M | $158.7M | +1,248 (+0.1%) | August 31, 2026 |
| 7 | American Funds SMALLCAP World A | 1.63% | 1.4M | $141.7M | −133,880 (−9.0%) | June 30, 2026 |
| 8 | State Street® SPDR® S&P® Biotech ETF | 1.30% | 1.1M | $112.9M | −20,500 (−1.9%) | September 30, 2026 |
| 9 | Vanguard MStar Small Cap Growth Indx Inv | 1.05% | 869K | $91.1M | −6,440 (−0.7%) | August 31, 2026 |
| 10 | T. Rowe Price Small-Cap Stock | 0.94% | 782K | $81.9M | +7,879 (+1.0%) | August 31, 2026 |
| 11 | Fidelity Small Cap Index | 0.82% | 685K | $71.7M | +5,673 (+0.8%) | July 31, 2026 |
| 12 | Vanguard Explorer Inv | 0.79% | 659K | $69.0M | +14,618 (+2.3%) | June 30, 2026 |
| 13 | T. Rowe Price Health Sciences | 0.77% | 641K | $67.1M | −202,600 (−24.0%) | August 31, 2026 |
| 14 | Fidelity Growth Company K6 | 0.74% | 619K | $64.9M | +2,500 (+0.4%) | August 31, 2026 |
| 15 | T. Rowe Price All-Cap Opportunities Fund | 0.73% | 608K | $63.7M | −26,409 (−4.2%) | August 31, 2026 |
| 16 | T. Rowe Price Growth Stock | 0.72% | 602K | $63.1M | +602,243 (0.0%) | August 31, 2026 |
| 17 | iShares Biotechnology ETF | 0.70% | 583K | $61.0M | −4,416 (−0.8%) | September 30, 2026 |
| 18 | T. Rowe Price Integrated US Sm Gr Eq | 0.68% | 567K | $59.4M | — | August 31, 2026 |
| 19 | Fidelity Select Biotechnology | 0.67% | 556K | $58.3M | — | August 31, 2026 |
| 20 | Fidelity Series Growth Company | 0.67% | 554K | $58.0M | +2,200 (+0.4%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
KYMR insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | Bruce Booth | Sell | $89.96 | 5,900 | $530,764 |
| 2026-04-22 | Jeremy G Chadwick | Sell | $90.00 | 300 | $27,000 |
| 2026-04-22 | Bruce Booth | Sell | $90.08 | 100 | $9,008 |
| 2026-04-15 | Bruce Booth | Sell | $89.95 | 2,200 | $197,890 |
| 2026-04-15 | Bruce Booth | Sell | $90.10 | 3,135 | $282,464 |
| 2026-04-15 | Jeremy G Chadwick | Sell | $90.00 | 1,300 | $117,000 |
| 2026-04-14 | Bruce Booth | Sell | $89.97 | 4,159 | $374,185 |
| 2026-04-14 | Jeremy G Chadwick | Sell | $90.00 | 5,251 | $472,590 |
| 2026-04-14 | Noah Goodman | Sell | $90.00 | 1,347 | $121,230 |
| 2026-04-10 | Noah Goodman | Sell | $87.35 | 2,000 | $174,700 |
| 2026-04-09 | Noah Goodman | Sell | $87.50 | 8,264 | $723,100 |
| 2026-04-01 | Jeremy G Chadwick | Sell | $85.46 | 14,640 | $1.3M |
| 2026-04-01 | Elena Ridloff | Sell | $85.42 | 4,600 | $392,932 |
| 2026-03-31 | Elena Ridloff | Sell | $85.37 | 7,400 | $631,738 |
| 2026-03-31 | Jeremy G Chadwick | Sell | $85.38 | 7,600 | $648,888 |
| 2026-03-25 | Jeremy G Chadwick | Sell | $80.26 | 24,727 | $2.0M |
| 2026-03-23 | Jeremy G Chadwick | Sell | $77.41 | 91,250 | $7.1M |
| 2026-03-11 | Jeremy G Chadwick | Sell | $83.30 | 25,758 | $2.1M |
| 2026-03-04 | Jared Gollob | Sell | $85.30 | 4,895 | $417,544 |
| 2026-03-04 | Jeremy G Chadwick | Sell | $85.30 | 3,919 | $334,291 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
KYMR shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns KYMR
Institutional investors own 119.4% of Kymera Therapeutics's shares and insiders 2.12%. The largest holder is FMR Inc with 14.85% of the shares (12.3M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 7 reduced their stake in the latest filings. Short interest is 15.33% of the float, or 13.18 days of average trading volume. The share count rose 89.5% since 2019.
Related: KYMR analyst forecast, KYMR key metrics. See the KYMR stock overview for the latest quote and news.
KYMR ownership FAQ
Who owns the most Kymera Therapeutics stock?
The largest shareholders of Kymera Therapeutics are FMR Inc (14.85%), Baker Bros Advisors LP (10.41%), venBio Select Advisor LLC (8.99%), T. Rowe Price Associates, Inc. (8.55%), T. Rowe Price Investment Management,Inc. (7.53%).
What percentage of Kymera Therapeutics is owned by institutions?
Institutions hold 119.4% of Kymera Therapeutics's shares outstanding; insiders hold 2.12%.
Which funds own Kymera Therapeutics?
The largest fund holders of Kymera Therapeutics are Fidelity Growth Company Fund (2.70%), Vanguard MStar Total Stk Mkt Idx Invest (2.52%), T. Rowe Price New Horizons (2.43%), Vanguard Health Care Inv (2.16%), iShares Russell 2000 ETF (1.95%).
What is Kymera Therapeutics's short interest?
9.9M shares of Kymera Therapeutics were sold short, 15.33% of the float; at the average daily volume it would take 13.18 days to cover.
Are insiders buying or selling Kymera Therapeutics?
Of the latest 20 reported insider transactions in Kymera Therapeutics (since March 4, 2026), 0 were purchases and 20 were sales.
How many shares of Kymera Therapeutics are outstanding?
Kymera Therapeutics has 82.3M shares outstanding, of which 66.0M are in the public float.